Position in PVLA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$16,777,890
New position
Shares Held
134,600
first reported quarter
Ownership
0.938%
of shares outstanding
% of Portfolio
0.34%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 34.54680534918276.ToString("F0")%
Shared 0.ToString("F0")%
None 65.45319465081724.ToString("F0")%
Derivatives in PVLA
reported options exposure · as of Mar 31, 2026CallValue
$6,232,500
CallShares
50,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026ORBIMED ADVISORS LLC holds $2,871,604,021 across 72 Biotechnology names. PVLA ranks #38 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EWTX |
Edgewise Therapeutics, Inc.
|
15,518,492 | $488,832,498 | |
| 2 | ELVN |
Enliven Therapeutics, Inc.
|
7,959,538 | $312,013,889 | |
| 3 | SION |
Sionna Therapeutics, Inc.
|
3,530,702 | $141,545,843 | |
| 4 | MBX |
MBX Biosciences, Inc.
|
3,637,887 | $108,590,926 | |
| 5 | CRVS |
Corvus Pharmaceuticals, Inc.
|
7,165,006 | $104,824,037 | |
| 6 | ARGX |
Argenx SE
|
136,900 | $99,971,225 | |
| 7 | CMPX |
Compass Therapeutics, Inc.
|
15,219,994 | $80,513,768 | |
| 8 | GPCR |
Structure Therapeutics Inc.
|
1,475,403 | $71,114,424 |
All Filings in PVLA
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,232,500 | 50,000 | Call | Defined | 2026-05-15 | |
| 2026-03-31 | $16,777,890 | 134,600 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||